Overview
- Envudeucitinib met all primary and secondary endpoints with high statistical significance in the ONWARD1 and ONWARD2 Phase 3 trials.
- Across both studies, 74% achieved PASI 75 and 59% reached sPGA 0/1 at Week 16, deepening to about 65% at PASI 90 and over 40% at PASI 100 by Week 24.
- The oral TYK2 inhibitor showed superiority to placebo on co‑primary endpoints and demonstrated clear separation on PASI 90 as early as Week 4.
- Safety through Week 24 was generally well tolerated and aligned with the Phase 2 profile.
- Alumis plans to present additional ONWARD data at a medical meeting and to submit an NDA in H2 2026, as shares jumped to $17.91 for a roughly 116% intraday gain.